EGFR and non-small cell lung carcinoma: The FLAURA study is a phase III study in 556 EGFR mutant (exon 19 del or L858R) advanced NSCLC patients which randomized patients 1:1 to a standard of care EGFR TKI (erlotinib or gefitinib) or osimertinib (67).